A retrospective cohort study reported that starting GLP-1 receptor agonist therapy was associated with lower follow-up C-reactive protein levels compared with initiating DPP-4 inhibitors in patients with type 2 diabetes. The analysis frames inflammation as a downstream clinical risk-modifier rather than a direct efficacy endpoint. While the study design cannot establish causality, the finding adds to the mechanistic narrative that incretin-based therapies may shift inflammatory biology alongside glycemic control. The comparison against DPP-4 initiation is notable because it reduces confounding tied to “incretin class” selection. For biotech teams developing cardiometabolic assets, inflammatory biomarker movement continues to be a key supporting layer for risk reduction strategies.
Get the Daily Brief